Plant Name: Lycium barbarum
Taxonomic Information:
Plant ID: NPO23429
Plant Latin Name: Lycium barbarum
Taxonomy Genus: Lycium
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
112863
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; South Korea; IndiaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Antibacterial; Anticholesterolemic; Antipyretic; Cancer; Diuretic; Hypoglycaemic; Ophthalmic; Purgative; Skin; Tonic; Vasodilator
Geographical Distribution:
India; South Korea; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; CHRM1; CHRM2; CHRM3; CHRM5; | |
| ACHE; | |
| BLM; HSD17B1; HSD17B10; ALOX15; | |
| GABRR1; | |
| CDK8; CSNK2A1; | |
| CA2; CA12; CA9; | |
| ESR2; | |
| MMP9; MMP1; MMP2; | |
| HIF1A; NFKB1; | |
| KMT2A; | |
| SLCO1B1; | |
| LMNA; FABP3; FABP4; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 4.509E-11 | 4.909E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 4.509E-11 | 4.909E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 1.351E-10 | 8.102E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.882E-09 | 8.195E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.681E-08 | 3.661E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.288E-08 | 8.857E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.803E-08 | 1.037E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 1.539E-07 | 1.675E-04 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.913E-07 | 3.704E-04 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.443E-06 | 1.565E-03 | CA12, CA2, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.270E-06 | 2.015E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.415E-06 | 4.659E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.044E-05 | 4.680E-03 | BLM, CA12, CA2, CA9, ESR2, KMT2A, MMP1, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.547E-05 | 6.016E-03 | FABP3, FABP4, FFAR4 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 1.547E-05 | 6.016E-03 | CHRM1, CHRM3, CHRM5 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.726E-05 | 6.593E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.850E-05 | 6.760E-03 | CA2, CA9, CSNK2A1, CYP1A2, FABP3, FFAR4, NFKB1, TSHR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.909E-05 | 6.816E-03 | CYP1A1, CYP1A2 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.014E-05 | 6.917E-03 | CA2, CA9, CHRM3, SLCO1B1, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 3.179E-05 | 9.749E-03 | CHRM1, CHRM3 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.138E-05 | 9.749E-03 | CYP19A1, CYP1A1, CYP2C19 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.223E-08 | 5.850E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.367E-06 | 6.380E-05 | CHRM2, CHRM3, ACHE, CHRM1, CHRM5 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.709E-06 | 6.380E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 7.744E-06 | 1.735E-04 | CHRM2, CHRM3, GABRR1, CHRM1, CHRM5, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.247E-05 | 2.328E-04 | CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.640E-05 | 6.223E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.283E-06 | 9.192E-05 | CA12, CA2, CA9 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 5.000E-05 | 6.223E-04 | MMP1, MMP2, MMP9 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.739E-05 | 2.782E-04 | CYP1A2, ALOX15, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 2.672E-04 | 2.620E-03 | CHRM2, CHRM3, CHRM1, CHRM5 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.973E-04 | 4.460E-03 | MMP1, MMP2, HIF1A, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.911E-04 | 3.369E-03 | CHRM2, CHRM1, NFKB1, TSHR |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 5.145E-04 | 4.116E-03 | CHRM2, CHRM3, CHRM1, CHRM5 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.808E-04 | 2.620E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.377E-04 | 2.620E-03 | FABP3, FABP4, MMP1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.864E-04 | 4.804E-03 | MMP2, MMP9, ESR2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; CHRM1; CHRM5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; CHRM3; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; CHRM1; CHRM2; CHRM3; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| NA: NA | Edema | NA | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| NA: NA | Addiction | NA | CHRM2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; ACHE; HIF1A; MMP9; MMP2; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; CHRM5; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; CHRM1; CHRM3; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; CHRM1; CHRM2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM5; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
| NA: NA | Dystonia | NA | CHRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MMP9; MMP2; CA9; |
| NA: NA | Spasms | NA | CHRM3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
